EBC-1

EBC1/EBC1细胞系/EBC1细胞株/EBC1人肺腺癌细胞

Cell line name EBC-1

Synonyms EBC-1/original; EBC1

Accession CVCL_2891

Resource Identification Initiative To cite this cell line use: EBC-1 (RRID:CVCL_2891)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Population: Chinese; Taiwan.

Doubling time: 42 hours (DOI=10.4044/joma1947.97.7-8_691); 38.7 hours (PubMed=8286010).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.

Sequence variations

Mutation; HGNC; 2731; DDR2; Simple; p.Thr681Ile (c.2042C>T); ClinVar=VCV001435412; Zygosity=Heterozygous (PubMed=28676216; Cosmic-CLP=753554).

Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous; Note=In 10% of cells (PubMed=16105816).

Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (PubMed=10536175; PubMed=20557307; Cosmic-CLP=753554; DepMap=ACH-000563).

HLA typing Source: PubMed=26589293

Class I

HLA-A A*24:02,24:02

HLA-B B*07:02,07:02

HLA-C C*07:02,07:02

Class II

HLA-DQ DQA1*01:01,01:01

DQB1*05:01,05:01

HLA-DR DRB1*01:01,15:01

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 1.01

Native American 0

East Asian, North 85.35

East Asian, South 10.91

South Asian 0

European, North 0

European, South 2.73

Disease Lung squamous cell carcinoma (NCIt: C3493)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_LC83 (EBC-1 KRAS (G12D/+/+/+)) CVCL_U892 (EBC-1/bone) CVCL_U893 (EBC-1/brain)

Sex of cell Male

Age at sampling 69Y

Category Cancer cell line

STR profile Source(s): Cosmic-CLP=753554; JCRB=JCRB0820; PubMed=25877200; RCB=RCB1965; TKG=TKG 0481

 

Markers:

Amelogenin X

CSF1PO 10

D3S1358 15

D5S818 11

D7S820 10,11

D8S1179 14

D13S317 12

D16S539 8,9 (RCB=RCB1965)

9 (Cosmic-CLP=753554; JCRB=JCRB0820; PubMed=25877200; TKG=TKG 0481)

D18S51 12,17

D21S11 29,30

FGA 22

Penta D 13

Penta E 16

TH01 7

TPOX 8

vWA 16,17

 

Run an STR similarity search on this cell line

Publications

DOI=10.2482/haigan.22.53

Hiraki S., Miyai M., Seto T., Tamura T., Watanabe Y., Ozawa S., Ikeda H., Nakata Y., Ohnoshi T., Kimura I.

Establishment of human continuous cell lines from squamous cell, adeno- and small cell carcinoma of the lung and the results of heterotransplantation.

Nihon Haigan Gakkai 22:53-58(1982)

 

DOI=10.4044/joma1947.97.7-8_691

Watanabe Y.

Experimental model of human lung cancer, Part I. Establishment and characterization of new tissue culture cell lines from human squamous cell carcinoma and adenocarcinoma of the lung.

Okayama Igakkai Zasshi 97:691-700(1985)

 

DOI=10.4044/joma1947.97.7-8_701

Watanabe Y.

Experimental model of human lung cancer, Part II Heterotransplantation of human continuous cell lines from squamous cell carcinoma and adenocarcinoma of the lung.

Okayama Igakkai Zasshi 97:701-712(1985)

 

PubMed=8286010

Kiura K., Watarai S., Shibayama T., Ohnoshi T., Kimura I., Yasuda T.

Inhibitory effects of cholera toxin on in vitro growth of human lung cancer cell lines.

Anticancer Drug Des. 8:417-428(1993)

 

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

 

PubMed=10358721; DOI=10.18926/AMO/31626

Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K., Kohara H., Harada M.

Establishment of a drug sensitivity panel using human lung cancer cell lines.

Acta Med. Okayama 53:67-75(1999)

 

PubMed=10536175; DOI=10.3892/ijo.15.5.927

Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.

Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.

Int. J. Oncol. 15:927-934(1999)

 

PubMed=11005564; DOI=10.1038/sj.neo.7900094; PMCID=PMC1550293

Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M., Yokota J.

Mutation and expression of the DCC gene in human lung cancer.

Neoplasia 2:300-305(2000)

 

PubMed=12569360; DOI=10.1038/sj.onc.1206106

Funakoshi T., Tachibana I., Hoshida Y., Kimura H., Takeda Y., Kijima T., Nishino K., Goto H., Yoneda T., Kumagai T., Osaki T., Hayashi S., Aozasa K., Kawase I.

Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer.

Oncogene 22:674-687(2003)

 

PubMed=14581340

Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.

TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.

Clin. Cancer Res. 9:4705-4713(2003)